Michael Aberman joins Regeneron
Former Wall Street analyst joins firm at pivotal time
Prior to joining Regeneron, Aberman spent six years as a Wall Street research analyst covering the biotechnology industry. Most recently, he was director and senior biotechnology analyst at Credit Suisse and before that, vice president and biotech analyst at Morgan Stanley. Before moving to Wall Street, Aberman was director of business development at Antigenics, an oncology-focused biotechnology company.
‘I am very excited to be joining Regeneron at a pivotal time in its history,’ said Aberman. ‘2010 will bring results from multiple Phase III trials in gout, age-related macular degeneration, and cancer. In addition, the expanded collaboration with Sanofi-Aventis positions Regeneron to capitalise on its capabilities to build a robust pipeline of antibody-based product candidates over the coming years.’
You may also like
Regulatory
Sanofi and Regeneron announce Marketing Authorisation Application for Dupixent (dupilumab) accepted for review by the EMA
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for Dupixent® (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables